Zheng, Guangrong

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 688

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications

Protein Degradation and InhibitorsTelomeres, Telomerase, and Senescence

Cited by 280

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Wang, Y., Chang, J., Liu, X., Zhang, X., Zhang, S., Zhang, X., Zhou, D., & Zheng, G. (2016) · Aging

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 274

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Khan, S., He, Y., Zhang, X., Yuan, Y., Pu, S., Kong, Q., Zheng, G., & Zhou, D. (2020) · Oncogene

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 252

The curcumin analog EF24 is a novel senolytic agent

Li, W., He, Y., Zhang, R., Zheng, G., & Zhou, D. (2019) · Aging

Telomeres, Telomerase, and SenescenceCurcumin's Biomedical Applications

Cited by 164

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Lv, D., Pal, P., Liu, X., Jia, Y., Thummuri, D., Zhang, P., Hu, W., Pei, J., Zhang, Q., Zhou, S., et al. (2021) · Nature Communications

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 158

DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas

He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 139

Oxidation resistance 1 is a novel senolytic target

Zhang, X., Zhang, S., Liu, X., Wang, Y., Chang, J., Zhang, X., Mackintosh, S. G., Tackett, A. J., He, Y., Lv, D., et al. (2018) · Aging Cell

Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model Organisms

Cited by 127

Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsUbiquitin and proteasome pathways

Cited by 126

Vesicular monoamine transporter 2: Role as a novel target for drug development

Zheng, G., Dwoskin, L. P., & Crooks, P. A. (2006) · The AAPS Journal

Parkinson's Disease Mechanisms and TreatmentsNeurotransmitter Receptor Influence on Behavior

Cited by 125

Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity

Zhang, X., Thummuri, D., Liu, X., Hu, W., Zhang, P., Khan, S., Yuan, Y., Zhou, D., & Zheng, G. (2020) · European Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 123

PROTAC therapy as a new targeted therapy for lung cancer

Li, J. W., Zheng, G., Kaye, F. J., & Wu, L. (2023) · Molecular Therapy

Protein Degradation and InhibitorsLung Cancer Treatments and Mutations

Cited by 87

Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-X L

Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 86

Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation

Liu, X., Wang, Y., Zhang, X., Gao, Z., Zhang, S., Shi, P., Zhang, X., Song, L., Hendrickson, H., Zhou, D., et al. (2018) · Bioorganic & Medicinal Chemistry

Telomeres, Telomerase, and SenescencePiperaceae Chemical and Biological Studies

Cited by 77

Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines

Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 71

BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Khan, S., Wiegand, J., Zhang, P., Hu, W., Thummuri, D., Budamagunta, V., Hua, N., Jin, L., Allegra, C. J., Kopetz, S. E., et al. (2022) · Journal of Hematology & Oncology

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 62

Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition

Pal, P., Thummuri, D., Lv, D., Liu, X., Zhang, P., Hu, W., Poddar, S. K., Hua, N., Khan, S., Yuan, Y., et al. (2021) · Journal of Medicinal Chemistry

Protein Degradation and InhibitorsCell death mechanisms and regulation

Cited by 60